{"prompt": "['2016N298481_02', 'CONFIDENTIAL', '205270', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'inflammatory infiltrates) was observed at doses of 0.8 mg/kg/day and', 'above, although total incidence and severity distribution within any', 'daprodustat-group were within historical control ranges. This is', 'consistent with an equivocal threshold for exacerbation of', 'spontaneous, progressive cardiomyopathy at 0.8 mg/kg/day which is', 'also the threshold dose for observing increased Hct values in', 'inndividual rats.', 'Cardiomyopathy has not been associated with naturally occurring', 'mutation in man which results in increased HIF stabilization.', 'ECHO assessments performed in phase 2b studies (24 weeks', 'treatment duration) did not identify any clinically meaningful changes in', 'LVEF for daprodustat.', 'Integrated AE data from clinical trials with daprodustat [including 2', 'global phase 2b studies (24-week treatment duration) and 2 Japanese', 'phase 3 studies (52-week treatment duration)]: No meaningful', 'difference was seen between treatment groups in reports of this AESI', '[1 (0.1%) daprodustat VS. 1 (0.2%) rhEPO; 0.64 relative risk (95%', 'confidence interval: 0.02, 18.07)].', 'Following review of clinical data received to date, this has not been', 'identified as a safety concern for daprodustat.', 'Proliferative retinopathy, macular edema, choroidal', 'Increases in local (ocular) VEGF production with retinal', 'Instream monitoring of safety data by internal', 'neovascularization', 'neovascularization and macular edema observed in diabetic', 'safety review team.', 'retinopathy and to choroidal leakage, edema and neovascularization', 'seen in age-related macular degeneration [Campochiaro, 2006].', 'Administration of 60 mg/kg daprodustat to mice caused minimal', 'increases in circulating VEGF while significant EPO increases were', 'observed.', 'No ocular abnormalities with daprodustat were seen in non-clinical', 'studies of up to 13 weeks duration in mice and dogs, 26 weeks in rats,', '27']['2016N298481_02', 'CONFIDENTIAL', '205270', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'and 39 weeks in monkeys.', 'In clinical studies up to 4 weeks duration, a dose-ordered increase in', 'VEGF plasma concentrations was observed at doses ranging from 10', 'to 150 mg administered once daily and from 10 to 30mg administered', 'three times weekly In studies up to 24 weeks duration at doses up to', '25mg, changes in VEGF plasma concentrations were variable but', 'similar relative to control.', 'Ophthalmologic assessments performed in phase 2b studies (24', 'weeks treatment duration) did not identify any clinically meaningful', 'changes in proliferative retinopathy, macular edema, or choroidal', 'neovascularization with daprodustat.', 'Integrated AE data [including 2 global phase 2b studies (24-week', 'treatment duration) and 2 Japanese phase 3 studies (52-week', 'treatment duration)]: No meaningful difference was seen between', 'treatment groups in reports of this AESI [9 (2.9%) daprodustat VS. 6', '(2.5%) rhEPO; 1.19 relative risk; (95% confidence interval: 0.42,', '3.43)].', 'Following review of clinical data with daprodustat received to date, this', 'has not been identified as a safety concern for daprodustat.', 'Exacerbation of rheumatoid arthritis', 'In inflamed rheumatic joints, activation of HIF- related genes', 'Instream monitoring of safety data by internal', 'secondary to decreased oxygen and pro-inflammatory cytokines has', 'safety review team.', 'been postulated to contribute to the neo-angiogenesis, proliferation', 'and infiltration of rheumatoid synovial fibroblasts [Westra, 2010; Muz,', '2009].', 'No abnormalities seen in non-clinical studies conducted to date for', 'daprodustat.', 'Integrated AE data [including 2 global phase 2b studies (24-week', 'treatment duration) and 2 Japanese phase 3 studies (52-week', 'treatment duration)] : No meaningful difference was seen between', '28']\n\n###\n\n", "completion": "END"}